Association of Fcγ Receptor IIa Genotype With Chronic Periodontitis in Caucasians

Yamamoto, Kouji; Kobayashi, Tetsuo; Grossi, Sara G.; Ho, Alex; Genco, Robert J.; Yoshie, Hiromasa; Nardin, Ernesto De

doi:10.1902/jop.2004.75.4.517

Cited by 54 publications

(64 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Es sabido que una dificultad para comparar los distintos estudios es la falta de consenso y homogeneidad de criterios, al usarse diferentes definiciones de periodontitis, las que incluyen: periodontitis crónica, estatus periodontal, enfermedad periodontal, periodontitis del adulto, pacientes con periodontitis, enfermedad periodontal refractaria, periodontitis juvenil localizada, periodontitis agresiva localizada/generalizada, además de pacientes resistentes a periodontitis, a lo que se suma el uso de distintas definiciones de umbral diagnóstico o la ausencia de una definición clara de éste. (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26) . Por lo mismo, hay coincidencia en que el umbral diagnós-tico, debe ser "preciso, consistente y relativamente precoz en la historia natural de la enfermedad" (1,2) .…”

Section: Test De La Probabilidad Exacta De Fisherunclassified

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.

Hidrobo-Ortiz

Poggi-Mayorga

Padilla-Pérez

et al. 2018

Rev. Clin. Periodoncia Implantol. Rehabil. Oral

View full text Add to dashboard Cite

trabajo investigación caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor Fcγriia.Characterization of a sample of Chilean patients with periodontitisand frequency of H131R polymorphism in the FcγRIIa receptor. Los receptores Fcγ (FcγR), específicos para la inmunoglobulina G, les confieren a las células donde se expresan funciones en la respuesta inmunoinflamatoria. La heterogeneidad interindividual en la eficiencia de la función de los FcγR se ha explicado por polimorfismos en los genes que codifican 3 de estos receptores, FcγRIIa, FcγRIIIa y FcγRIIIb, los cuales han sido asociados con susceptibilidad y/o severidad en enfermedades infecciosas y autoinmunes en diferentes poblaciones. En este trabajo se analizan las características clínicas de 94 pacientes chilenos con evidencia de daño periodontal y se establece la frecuencia alélica/genotípica del polimorfismo H131R en el gen FCGR2A que codifica para el receptor FcγRIIa, así como su posible asociación con periodontitis. El polimorfismo G>A (H131R) en el gen FCGR2A se estudió por PCR en tiempo real utilizando sondas TaqMan. En el grupo estudiado se encontró un alto porcentaje de pacientes con periodontitis (86, 2%) y una asociación significativa a edad y sexo. No se observó una asociación a los alelos H o R, ni a los genotipos encontrados (H/R y R/R). Este es el primer trabajo en que se estudia el polimorfismo H131R en el FcγRIIa en población chilena en una muestra de pacientes adecuadamente caracterizados; sin embargo, creemos que es necesario estudiar un mayor número de sujetos para determinar si los polimorfismos de los genes FcγR constituyen o no posibles factores de susceptibilidad a enfermedad periodontal en población chilena. Palabras clavePolimorfismo R131H, Periodontitis, FCGR2A.Rev. Clin. Periodoncia Implantol. Rehabil. Oral Vol. 11(2); 84-90, 2018. abstractThe Fcγ receptors (FcγR) specific for the immunoglobulin G, express for the immune inflammatory response function. The inter individual heterogeneity in the efficiency of theFcγR function has been explained by polymorphisms in genes that encode for 3 of thesereceptors, FcγRIIa, FcγRIIIa and FcγRIIIb, which have been associated with susceptibilityor severity in autoimmune and infectious diseases in different populations. This paper discusses the clinical characteristics of 94 Chilean patients with evidence of periodontal damage and establishes the allelic/genotypic frequency of polymorphism H131R in theFCGR2A gene, which encodes for the receptor FcγRIIa, as well as their possible association with periodontitis. Polymorphism G>A (H131R) in the gene FCGR2A was studied via realtime PCR using TaqMan probes. In the study group, a high percentage of patients withperiodontitis was found (86, 2%) with a significant association with age and gender. No determination could be reached as to whether the allele H or R or the genotypes found(H/R and R/R) were a factor of genetic susceptibility.This is the first study to determine the polymorphisms...

show abstract

Section: Test De La Probabilidad Exacta De Fisherunclassified

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.

Hidrobo-Ortiz

Poggi-Mayorga

Padilla-Pérez

et al. 2018

Rev. Clin. Periodoncia Implantol. Rehabil. Oral

View full text Add to dashboard Cite

show abstract

“…The FcγRIIIb-NA2 allele and NA2/NA2 genotype occurred more frequently in controls and NA2/NA2 again more frequently in patients with the generalized aggressive form of periodontitis (GAgP) (16). The distribution of genotypes was significantly different among different races, and it seems that the relationship between FcγR polymorphisms and periodontal disease is associated with racial affiliation (9,23,49). Homozygous carriers of the polymorphism of a myeloperoxidase (−463 G / G) are at increased risk of periodontitis they are at the same time smokers (34).…”

Section: Gene Polymorphism In Periodontitismentioning

confidence: 99%

Trends in Laboratory Diagnostic Methods in Periodontology

Bolerázska

Mareková

Markovská

2016

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary: This work presents a summary of current knowledge on the laboratory diagnosis of periodontitis. It focuses on the theoretical foundations and is supplemented with new knowledge. It subsequently describes specifically the laboratory diagnosis methods of periodontitis: the protein expression of inflammation, oral microbiology and molecular diagnostics. Periodontitis is a serious disease worldwide and its confirmed association with systemic diseases means its severity is increasing. Its laboratory diagnosis has the potential to rise to the level of clinical and diagnostic imaging. The transfer of diagnostic methods from laboratory to clinical use is increasingly used in the prevention and monitoring of the exacerbation and treatment of periodontal disease, as well as of its impact on systemic disease.

show abstract

“…As with Etanercept, Trastuzumab may have a role in the therapy of systemic lupus erythematosus. The Fc-gamma receptor plays an important role in the treatment of SLE [53,54] and polymorphisms in this receptor show significant associations with periodontitis [55][56][57]. Because Trastuzumab has been shown to engage in the activation/inhibition of Fc-gamma [58], it may be able to modulate these two Fc-gamma-related diseases.…”

Section: Trastuzumabmentioning

confidence: 99%

A pathway profile-based method for drug repositioning

et al. 2012

View full text Add to dashboard Cite

Finding new applications for existing pharmaceuticals, known as drug repositioning, is a validated strategy for resolving the problem of high expenditure but low productivity in drug discovery. Currently, the prevalent computational methods for drug repositioning are focused mainly on the similarity or relevance between known drugs based on their "features", including chemical structure, side effects, gene expression profile, and/or chemical-protein interactome. However, such drug-oriented methods may constrain the newly predicted functions to the pharmacological functional space of the existing drugs. Clinically, many drugs have been found to bind "off-target" (i.e. to receptors other than their primary targets), which can lead to undesirable effects. In this study, which integrates known drug target information, we propose a disease-oriented strategy for evaluating the relationship between drugs and disease based on their pathway profile. The basic hypothesis of this method is that drugs exerting a therapeutic effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological process. Upon testing eight of the global best-selling drugs in 2010 (each with more than three targets), the FDA (Food and Drug Administration, USA)-approved therapeutic function of each was included in the top 10 predicted indications. On average, 60% of predicted results made using our method are proved by literature. This approach could be used to complement existing methods and may provide a new perspective in drug repositioning and side effect evaluation. Drug discovery is a time-consuming and laborious process. To bring a single de novo drug to the market, an average of more than $800 million is spent in a time period of ~15 years [1]. Moreover, about 90% of drugs fail during development in phase I clinical trials [2], a rate caused mainly by findings of low therapeutic efficacy and/or unacceptable toxicity [3,4]. Others are discovered to have similar drawbacks, even after approval by drug regulatory authorities (e.g. the US Federal Drug Administration (FDA)), or postmarketing. In exceptional circumstances, it is necessary to either modify the drug or even withdraw it from the market. The "thalidomide affair", a highly recognizable example of a drug having tragic unintended effects, is a typical example. Thalidomide was withdrawn from the market in the early 1960s because of teratogenic effects. However, it has since been reborn as an FDA-approved treatment for cancers and lepriasis owing to the discovery of new indications, namely immunomodulatory and anti-angiogenic activities [5][6][7][8].Despite enormous increases in novel technologies over recent times, the productivity of drug discovery efforts has actually decreased since the mid-1990s [9]. The need to define a novel strategy and/or utilize new resources in drug discovery is urgent. Drug repositioning, which aims to discover new indications for existing drugs, can shorten the development cycle and reduce the risk of u...

show abstract

Association of Fcγ Receptor IIa Genotype With Chronic Periodontitis in Caucasians

Cited by 54 publications

References 31 publications

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.

Trends in Laboratory Diagnostic Methods in Periodontology

A pathway profile-based method for drug repositioning

Contact Info

Product

Resources

About

Association of Fcγ Receptor IIa Genotype With Chronic Periodontitis in Caucasians

Cited by 54 publications

References 31 publications

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor Fc&#947;RIIa.

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor Fc&#947;RIIa.

Trends in Laboratory Diagnostic Methods in Periodontology

A pathway profile-based method for drug repositioning

Contact Info

Product

Resources

About

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.

Caracterización de una muestra de pacientes chilenos con periodontitis y frecuencia del polimorfismo H131R en el receptor FcγRIIa.